pharmadmin

Author

Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Los Angeles, California, October 2016 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced that it intends to offer for sale shares of its common stock in […]

Leave Your Comments »

Ritter Pharmaceuticals Concludes Last Patient Visit of its Phase 2b/3 Clinical Trial of RP-G28 for the Treatment of Lactose Intolerance

LOS ANGELES (October 17, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the last patient has completed dosing and all monitoring visits in its Phase 2b/3 clinical trial of RP-G28 for […]

Leave Your Comments »

Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum

LOS ANGELES (October 5, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s Chief Executive Officer, Michael Step, presented at the 4th Microbiome R&D Business Collaboration Forum & Panel on […]

Leave Your Comments »

Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in Lactose Intolerance

LOS ANGELES (August 15, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has completed patient enrollment on schedule for its Phase 2b/3 clinical trial of its investigational compound RP-G28 for […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

 Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update  LOS ANGELES (August 8, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the […]

Leave Your Comments »

Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28

Patent covers methods for treating symptoms associated with lactose intolerance and improving gastrointestinal health LOS ANGELES (June 28, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it recently has been issued […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update

LOS ANGELES (March 21, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutics that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the fourth quarter and full year ended December 31, 2015. 2015 and Recent Operational […]

Leave Your Comments »

Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance

LOS ANGELES (March 21, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutics that modulate the human gut microbiome to treat gastrointestinal diseases, today announced the dosing of the first patient in its Phase 2b/3 clinical trial of RP-G28 for the treatment of lactose intolerance. Andrew […]

Leave Your Comments »

Ritter Pharmaceuticals Initiates Phase 2B/3 Clinical Trial of RP-G28 in Lactose Intolerance

LOS ANGELES (March 14, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutics that modulate the human gut microbiome to treat gastrointestinal diseases, today announced initiation of its Phase 2B/3 clinical trial of RP-G28, which has the potential to be the first FDA-approved treatment for lactose […]

Leave Your Comments »

Ritter Pharmaceuticals to Present at the 28th Annual ROTH Conference

LOS ANGELES (March 10, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutics that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Michael Step, Chief Executive Officer, will present a corporate overview at the 28th Annual ROTH Conference on Tuesday, March 15, […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD